26 November, 2019 | Michael Avraam
Demand is increasing for better-targeted, more effective medications, leading to manufacturers handling more and more highly potent active pharmaceutical ingredients (HPAPIs). This has led to a natural increase in expectations around quality and process efficiencies. Because new and re-classified HPAPIs can present a challenge for existing manufacturing facilities, many firms look to outsource to specialists with the necessary controls and equipment.
In this article, ChargePoint’s head of solutions engineering, Michael Avraam, discusses how containment valves and smart monitoring technologies can help to mitigate risk in the manufacture of HPAPIs.
Read the article here: https://bit.ly/2PxeXu4